Research reveals post-Christmas cholesterol spike: Expert offers rescuing resolutions

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics ap­pears to be a weak­er pso­ri­a­sis treat­ment than some of its in­jectable com­pe­ti­tion, ac­cord­ing

CAM­BRIDGE, MA — When look­ing to the fu­ture of the drug in­dus­try, the al­lure of Boston is strong. This week, the Japan­ese drug­mak­er Astel­las be­came